SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

AstraZeneca Pharma reports net loss of Rs 33 crore in Q4

14 May 2012 Evaluate

AstraZeneca Pharma India has registered a net loss of Rs 33 crore for the quarter ended March 31, 2012, due to a voluntary recall of sterile products and temporary halt of production at its Bangalore facility. The company had posted a net profit of Rs 8.35 crore for the quarter ended March 31, 2011.

Total income of the company stood at Rs 91.78 crore for the quarter ended March 31, 2012. It was Rs 126.73 crore for the corresponding period previous fiscal, up by 27.58%.

The company said its board of directors has recommended a dividend of Rs 3.50 per equity share of face value of Rs 2 each for the financial year ended March 31, 2012.

AstraZeneca operates through two entities, AstraZeneca Pharma India and AstraZeneca India in the country.

Astrazeneca Pharma I Share Price

8508.80 -16.30 (-0.19%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×